Valneva: 94% antibody persistence with the IXCHIQ® vaccine

Valneva, a vaccine specialist, has announced promising results for its chikungunya vaccine, IXCHIQ®. In Lyon, the company revealed that 94% of participants maintained a seroresponse five years after a single dose. This persistence is reassuring, even in the elderly, and comparable to that of young adults. The vaccine thus offers lasting protection against a disease with unpredictable outbreaks.

These results echo previous data, supporting the crucial role of the vaccine in the fight against chikungunya, a mosquito-borne disease that is difficult to contain. With the support of CEPI and the European Union, studies will continue to better understand the long-term effectiveness of the vaccine. A vaccination campaign in Brazil has already vaccinated nearly 80,000 adults, demonstrating the vaccine's value in real-world conditions.